- Home
- ITRM vs LVTX Comparison
ITRM vs LVTX Comparison
Compare ITRM & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- LVTX
- Stock Information
- Founded
- ITRM 2015
- LVTX 2016
- Country
- ITRM Ireland
- LVTX Netherlands
- Employees
- ITRM N/A
- LVTX N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- LVTX Health Care
- Exchange
- ITRM Nasdaq
- LVTX Nasdaq
- Market Cap
- ITRM 40.0M
- LVTX 33.9M
- IPO Year
- ITRM 2018
- LVTX 2021
- Fundamental
- Price
- ITRM $0.97
- LVTX $1.31
- Analyst Decision
- ITRM Strong Buy
- LVTX Hold
- Analyst Count
- ITRM 2
- LVTX 3
- Target Price
- ITRM $7.00
- LVTX $1.75
- AVG Volume (30 Days)
- ITRM 501.9K
- LVTX 13.4K
- Earning Date
- ITRM 08-13-2025
- LVTX 08-19-2025
- Dividend Yield
- ITRM N/A
- LVTX N/A
- EPS Growth
- ITRM N/A
- LVTX N/A
- EPS
- ITRM N/A
- LVTX N/A
- Revenue
- ITRM N/A
- LVTX $4,990,000.00
- Revenue This Year
- ITRM N/A
- LVTX N/A
- Revenue Next Year
- ITRM $270.19
- LVTX N/A
- P/E Ratio
- ITRM N/A
- LVTX N/A
- Revenue Growth
- ITRM N/A
- LVTX N/A
- 52 Week Low
- ITRM $0.81
- LVTX $0.85
- 52 Week High
- ITRM $3.02
- LVTX $2.39
- Technical
- Relative Strength Index (RSI)
- ITRM 45.02
- LVTX 50.22
- Support Level
- ITRM $0.93
- LVTX $1.27
- Resistance Level
- ITRM $1.03
- LVTX $1.33
- Average True Range (ATR)
- ITRM 0.04
- LVTX 0.04
- MACD
- ITRM 0.00
- LVTX -0.00
- Stochastic Oscillator
- ITRM 29.23
- LVTX 35.71
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.